Twine Natalie C, Stover Jennifer A, Marshall Bonnie, Dukart Gary, Hidalgo Manuel, Stadler Walter, Logan Theodore, Dutcher Janice, Hudes Gary, Dorner Andrew J, Slonim Donna K, Trepicchio William L, Burczynski Michael E
Discovery Medicine, Wyeth Research, Cambridge, Massachusetts 02140, USA.
Cancer Res. 2003 Sep 15;63(18):6069-75.
Expression profiling has demonstrated that transcriptomes of primary malignancies differ from those in normal tissue. It is unknown, however, whether there exist "surrogate" transcriptional markers in peripheral blood mononuclear cells (PBMCs) of patients with solid tumors. We identified transcripts expressed differentially between PBMCs from renal cell carcinoma patients and normal subjects, some of which appear to reflect specific immune responses of circulating cells. We also identified small sets of predictor genes distinguishing PBMCs from renal cell carcinoma patients and normal volunteers with high accuracy. The present findings have important implications for diagnosis and future clinical pharmacogenomic studies of antitumor therapies.
表达谱分析表明,原发性恶性肿瘤的转录组与正常组织的不同。然而,实体瘤患者外周血单核细胞(PBMC)中是否存在“替代”转录标志物尚不清楚。我们鉴定了肾细胞癌患者与正常受试者PBMC之间差异表达的转录本,其中一些似乎反映了循环细胞的特异性免疫反应。我们还鉴定出了少量预测基因,能够高精度地区分肾细胞癌患者与正常志愿者的PBMC。本研究结果对抗肿瘤治疗的诊断及未来临床药物基因组学研究具有重要意义。